Clinical characteristics and anti-Saccharomyces cerevisiae antibody (ASCA) status of twins with Crohn’s disease according to the Vienna classification
| Twin individuals (n = 70)* | ASCA+ (n = 40) | ASCA− (n = 30) | |
|---|---|---|---|
| Percentages refer to total number of twins (n = 70). | |||
| *Data on CARD15/NOD2 genotype based on 68 twin individuals only. | |||
| †Arg702Trp, Gly908Arg, or Leu1007fsinsC. | |||
| Age at diagnosis | |||
| <40 y (A1) | 55 (79%) | 35 (50%) | 20 (29%) |
| ⩾40 y (A2) | 15 (21%) | 5 (7%) | 10 (14%) |
| Location | |||
| Terminal ileum (L1) | 28 (40%) | 20 (29%) | 8 (11%) |
| Colon (L2) | 21 (30%) | 6 (9%) | 15 (21%) |
| Ileocolon (L3) | 19 (27%) | 12 (17%) | 7 (10%) |
| Upper GI (L4) | 2 (3%) | 2 (3%) | 0 (0%) |
| Behaviour | |||
| Non-stricturing non-penetrating (B1) | 30 (43%) | 12 (17%) | 18 (26%) |
| Stricturing (B2) | 21 (30%) | 16 (23%) | 5 (7%) |
| Penetrating (B3) | 19 (27%) | 12 (17%) | 7 (10%) |
| CARD15/NOD2 genotype† | |||
| Wild-type | 56 (82%) | 34 (50%) | 22 (32%) |
| Heterozygote | 12 (18%) | 6 (9%) | 6 (9%) |
| Homozygote | 0 (0%) | 0 (0%) | 0 (0%) |